Similar articles

• [Changes of blood coagulability and effects of the platelet aggregation inhibitor (ticlopidine) in experimental subarachnoid hemorrhage in dogs].

  Toyoda O, Nukui H, Horikoshi S, Mitsuka S, Sasaki H, Tamada J, Miyagi O, Shibasaki T, Ohe C. Toyoda O, et al. Neurol Med Chir (Tokyo). 1985 Oct;25(10):810-7. doi: 10.2176/nmc.25.810. Neurol Med Chir (Tokyo). 1985. PMID: 2417133 Japanese. No abstract available.
• Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.

  Bernat A, Vallée E, Maffrand JP, Roncucci R. Bernat A, et al. Thromb Res. 1985 Jan 15;37(2):279-85. doi: 10.1016/0049-3848(85)90016-7. Thromb Res. 1985. PMID: 3975872
• Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.

  Ashida S, Sakuma K, Abiko Y. Ashida S, et al. Thromb Res. 1980 Mar 1;17(5):663-71. doi: 10.1016/0049-3848(80)90369-2. Thromb Res. 1980. PMID: 7385100 No abstract available.
• Overview: pharmacology of ticlopidine.

  Gordon JL. Gordon JL. Agents Actions Suppl. 1984;15:108-15. doi: 10.1007/BF01966992. Agents Actions Suppl. 1984. PMID: 6385643 Review. No abstract available.
• Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.

  Picard-Fraire C. Picard-Fraire C. Thromb Res Suppl. 1983;4:119-28. doi: 10.1016/0049-3848(83)90367-5. Thromb Res Suppl. 1983. PMID: 6356462 Review.